Medigene AG

XTRA:MDG1 Stock Report

Market Cap: €15.2m

Medigene Future Growth

Future criteria checks 1/6

Medigene is forecast to grow earnings and revenue by 11% and 13.3% per annum respectively while EPS is expected to grow by 25.7% per annum.

Key information

11.0%

Earnings growth rate

25.7%

EPS growth rate

Biotechs earnings growth42.3%
Revenue growth rate13.3%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Jan 03
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Aug 12
The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Aug 10
Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Nov 29
Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Jun 17
This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Mar 29
We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 16
How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Dec 23
How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Earnings and Revenue Growth Forecasts

XTRA:MDG1 - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268-11N/AN/A1
12/31/20255-12N/AN/A1
12/31/202411-12N/AN/A1
6/30/20247-16-15-14N/A
3/31/20247-16-15-15N/A
12/31/20236-16-16-15N/A
9/30/20238-23-15-14N/A
6/30/20239-29-15-13N/A
3/31/202320-19-2-1N/A
12/31/202231-81112N/A
9/30/20223111213N/A
6/30/202231101414N/A
3/31/202221012N/A
12/31/202110-10-11-11N/A
9/30/202110-16-14-14N/A
6/30/20219-22-17-17N/A
3/31/20218-25-21-21N/A
12/31/20208-29-24-25N/A
9/30/20209-25N/AN/AN/A
6/30/20209-23-26-27N/A
3/31/202010-21N/AN/AN/A
12/31/201911-20-17-16N/A
9/30/20199-23N/AN/AN/A
6/30/20199-23-15-14N/A
3/31/20198-19N/AN/AN/A
12/31/20188-21-10-10N/A
9/30/20188-18N/AN/AN/A
6/30/20188-16-9-11N/A
3/31/20188-16N/AN/AN/A
12/31/20178-16N/A-21N/A
9/30/20178-14N/AN/AN/A
6/30/20178-17N/A-7N/A
3/31/20178-12N/AN/AN/A
12/31/20167-9N/A-4N/A
9/30/20166-8N/AN/AN/A
6/30/20167-7N/A-14N/A
3/31/20167-11N/AN/AN/A
12/31/20157-13N/A-11N/A
9/30/201511-11N/A-9N/A
6/30/201511-9N/A-8N/A
3/31/201513-7N/A-8N/A
12/31/201413-6N/A-9N/A
9/30/201410-8N/A-9N/A
6/30/20149-7N/A-10N/A
3/31/20148-9N/A-12N/A
12/31/20138-10N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDG1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDG1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDG1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDG1's revenue (13.3% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: MDG1's revenue (13.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MDG1's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:07
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medigene AG is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xian DengBerenberg
Gary WaandersBryan Garnier & Co
Thibaud RutsaertGSN North America